Amicus Therapeutics Inc. (FOLD): What is the Risk Factor?

Amicus Therapeutics Inc. (NASDAQ:FOLD) saw an upside of 1.39% to close Monday at $11.67 after adding $0.16 on the day. The 5-day average trading volume is 3,280,920 shares of the company’s common stock. It has gained $11.79 in the past week. An average of 3,241,550 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,395,968.

FOLD’s 1-month performance is 6.77% or $0.74 on its low of $9.41 reached on 10/01/21. The company’s shares have touched a 52-week low of $8.60 and high of $25.39, with the stock’s rally to the 52-week high happening on 01/06/21. YTD, FOLD has lost -49.46% or -$11.42. However, the current price is down -54.04%% from the 52-week high price.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Insider Transactions

On Oct 01, 11 days have gone by since the last insider trading activity for Amicus Therapeutics Inc. (FOLD). Crowley John F (Chairman & CEO) most recently sold 7,500 shares at $10.00 per share on Oct 01. This transaction cost the insider $75,000. Chief Operating Officer, Campbell Bradley L, sold 10,515 shares at a price of $10.00 on Oct 01. Then, on Sep 15, Chairman & CEO Crowley John F sold 22,000 shares at a price of $11.08 per share. This transaction amounted to $243,828.

Valuation Metrics

Amicus Therapeutics Inc. (FOLD) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.FOLD stock has a beta of 1.18. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 10.81 while the price-to-book (PB) in the most recent quarter is 14.59.

Amicus Therapeutics Inc.’s quick ratio for the period ended June 29 was 4.10, with the current ratio over the same period at 4.30 meaning that FOLD stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 1.83, while the total debt to equity was 1.83. In terms of profitability, the gross margin trailing 12 months is 88.40%. The trailing 12-month EBITDA margin is -90.08% while for the period ending June 29; Amicus Therapeutics Inc.’s operating margin was -76.90%. The firm’s gross profit as reported stood at $229.84 million against revenue of $260.89 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Amicus Therapeutics Inc.’s cash and short-term investments amounted to $206.53 million against total debt of $441.74 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected FOLD to announce -$0.22 per share in earnings in its latest quarter, but it posted -$0.19, representing a 13.60% surprise. EBITDA for the quarter stood at more than -$36.62 million. FOLD stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 572.98 million, with total debt at $441.74 million. Shareholders hold equity totaling $266.56 million

Technical Picture

Let’s look briefly at Amicus Therapeutics Inc. (FOLD) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 66.94% to suggest the stock is trending Neutral, with historical volatility in this time period at 63.49%.

The stock’s 5-day moving average is $11.09, reflecting a +18.84% or $1.85 change from its current price. FOLD is currently trading +3.55% above its 20-day SMA, +30.25% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +25.62% and -51.82% respectively.

Stochastic %K and %D was 93.31% and 83.99% and the average true range (ATR) pointed at 0.59. The RSI (14) points at 61.72%, while the 14-day stochastic is at 94.96% with the period’s ATR at 0.55. The stock’s 9-day MACD Oscillator is pointing at 0.95 and 0.87 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Amicus Therapeutics Inc. (NASDAQ: FOLD), JP Morgan upgraded it to an Overweight rating. They previously had a Neutral rating on the stock. Analysts offering their rating for FOLD stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate FOLD as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.

What is FOLD’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $12.00 and a high of $29.00, with their median price target at $16.00. Looking at these predictions, the average price target given by analysts is for Amicus Therapeutics Inc. (FOLD) stock is $16.89.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam